MannKind Reports First Quarter 2026 Financial Results and Provides Business Update
MannKind reported Q1 2026 revenue of $90.2 million, up 15% year-over-year, driven by the launch of Furoscix and higher royalty revenues. The company highlighted two upcoming regulatory catalysts: the PDUFA date for Afrezza pediatric indication on May 29, 2026, and the Furoscix ReadyFlow Autoinjector on July 26, 2026.
Key figures
- Revenue
- 90171000
- Guidance
- Furoscix ReadyFlow PDUFA July 26, 2026; Afrezza pediatric PDUFA May 29, 2026
- Revenue Yoy
- 15%
- Furoscix sales
- 15500000
- Debt settlement
- 36300000
- Cash and equivalents
- 134000000
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.